Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 9,445 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetics Clear all
Recruiting Phase 1 Interventional

Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers

NCT04295863
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Nivolumab Standard, Pembrolizumab Standard, Nivolumab Extended, Pembrolizumab Extended
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Evaluating GSK2248761 and Raltegravir Pharmacokinetics in Healthy Adult Subjects

NCT01101893
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Raltegravir, GSK2248761, GSK2248761 + Raltegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 22, 2026, 2:43 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

NCT07477704
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
34
States / cities
Anniston, Alabama • Cullman, Alabama • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Results available

A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo)

NCT00942084
View directory record Official record
Conditions
Herpes Simplex Virus, Neonatal Sepsis
Interventions
Acyclovir
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
Up to 45 Days
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Wichita, Kansas • New Orleans, Louisiana • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)

NCT06575933
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Calderasib, Midazolam, Digoxin
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies

NCT00420615
View directory record Official record
Conditions
Solid Tumors
Interventions
Patupilone and Omeprazole, Patupilone + Midalzolam
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

NCT00864487
View directory record Official record
Conditions
Healthy Subjects
Interventions
Neratinib
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2012 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods

NCT02456584
View directory record Official record
Conditions
Contraception
Interventions
DMPA 150, DMPA 300, DMPA 104
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

NCT03962049
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
Linzagolix
Drug
Lead sponsor
ObsEva SA
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
BI 3802876, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional Results available

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

NCT01525225
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

NCT00747825
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
131-I-MIP-1145
Drug
Lead sponsor
Molecular Insight Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids

NCT02630563
View directory record Official record
Conditions
Pediatric Liver Transplantation
Interventions
Corticosteroids, Cyclosporine, mycophenolate mofetil
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
3 Months to 12 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

NCT02502149
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
rFVIIIFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

NCT03565315
View directory record Official record
Conditions
Healthy Adult Immune Response
Interventions
VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Dose Escalation Study in de Novo Renal Transplantation

NCT04311632
View directory record Official record
Conditions
Kidney Transplantation
Interventions
TCD601, Tacrolimus (TAC), Corticosteroids (CS), Mycophenolate Mofetil (MMF), ATG
Biological · Drug
Lead sponsor
ITB-Med LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Kansas City, Kansas • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure

NCT02157506
View directory record Official record
Conditions
Heart Failure, Decompensated Heart Failure, Acute Heart Failure
Interventions
CXL-1427, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
14
States / cities
Gainesville, Florida • Jacksonville, Florida • Macon, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

NCT05090904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Gainesville, Florida • Augusta, Georgia • Glenview, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

NCT05718921
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
Drug
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacokinetics and Pharmacodynamics of Fructose

NCT00661947
View directory record Official record
Conditions
Healthy
Interventions
Dr Pepper sweetened with sucrose or high fructose corn syrup
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years to 5 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2010 · Synced Oct 22, 2026, 2:43 AM EDT
Completed Phase 1 Interventional

A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)

NCT01671904
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Bendamustine, Obinutuzumab, Rituximab, Venetoclax
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 22, 2026, 2:43 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 2:43 AM EDT